Subscribe
shutterstock_1572740566_nitpicker
nitpicker / Shutterstock.com
13 April 2021Big PharmaRory O'Neill

Sanofi and C4X in $493m licensing deal

UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million ($493 million), which will see the French pharmaceutical company develop anti-inflammatory therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
PTAB invalidates Sanofi injector patent
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Medtech
PTAB invalidates Sanofi injector patent
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More on this story

Medtech
PTAB invalidates Sanofi injector patent
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility